WhatsApp
backNews Article

Viyash Scientific Limited Reports 17.8% Revenue Growth and 49.4% Profit Rise for H1 FY27 with Strategic Expansion Moves

Company completes BioForLife acquisition in Italy and advances investments in oncology and manufacturing capacities

Viyash Scientific Limited announced a 17.8% increase in revenue to ₹19,343 million and a 49.4% rise in profit after tax to ₹1,639 million for the half year ended September 30, 2026. The company also completed the acquisition of BioForLife in Italy and is investing in oncology capabilities and capacity expansion.

6 days ago|VIYASH-1.12%
Viyash Scientific LimitedBSE:512529NSE:VIYASHGeneral / Other

Viyash Scientific Limited

General / Other

Viyash Scientific Limited posted a 17.8% increase in revenue to ₹19,343 million and a 49.4% rise in profit after tax to ₹1,639 million for the half year ended September 30, 2026, reflecting growth across its integrated pharmaceutical operations.

The company’s EBITDA before ESOP costs rose 29.9% to ₹4,124 million, with a margin of 21.3% for H1 FY27. Its Q2 revenue alone reached ₹9,879 million, up 16.2% year-over-year, while EBITDA grew 10.3% to ₹2,077 million.

Viyash Scientific completed the acquisition of BioForLife in Italy, enhancing its position in the companion animal health segment. Additionally, the company is investing in new oncology capabilities, an in-house facility for companion animal manufacturing, and expanding its API production capacity to meet increasing customer demand.

The company reported a net debt to EBITDA ratio of 0.0x for the quarter, down from 0.7x the previous year, indicating improved debt management.

An earnings call to discuss the results and company outlook was scheduled for November 14, 2026.

Highlights

  • H1 FY27 revenue of ₹19,343 million, up 17.8% year-over-year
  • Profit after tax for H1 FY27 reached ₹1,639 million, up 49.4%
  • Q2 FY27 revenue at ₹9,879 million with a 16.2% year-over-year increase
  • EBITDA before ESOP costs for H1 FY27 at ₹4,124 million, representing a 29.9% increase
  • Completed acquisition of BioForLife in Italy to strengthen companion animal platform
  • Investments underway in oncology capabilities and manufacturing expansion for companion animal products

Key Data Snapshot

H1 FY27 Revenue from Operations₹ 19,343 Mn
H1 FY27 Profit After Tax (PAT)₹ 1,639 Mn
H1 FY27 EBITDA before ESOP costs₹ 4,124 Mn
Q2 FY27 Revenue from Operations₹ 9,879 Mn
Q2 FY27 Profit After Tax (PAT)₹ 847 Mn
Q2 FY27 EBITDA before ESOP costs₹ 2,077 Mn
Net Debt/EBITDA Ratio Q2 FY270.0x
Acquisition CompletedBioForLife, Italy
Earnings Call Date and TimeNovember 14, 2026, 11:00 AM IST

What happened

  • Viyash Scientific Limited reported financial results for the quarter and half year ended September 30, 2026.
  • Revenue for H1 FY27 increased by 17.8% to ₹19,343 million compared to H1 FY26.
  • Profit after tax for H1 FY27 rose 49.4% to ₹1,639 million year-over-year.
  • EBITDA before ESOP costs for H1 FY27 improved 29.9% to ₹4,124 million.
  • Net debt to EBITDA ratio improved to 0.0x from 0.7x a year ago.

Key details

  • Q2 FY27 revenue stood at ₹9,879 million, up 16.2% year-over-year, with EBITDA of ₹2,077 million at a 21.0% margin.
  • Adjusted PAT for Q2 FY27 with normalized ESOP cost is ₹1,110 million.
  • The acquisition of BioForLife in Italy was completed, strengthening the company's companion animal platform.
  • Viyash Scientific is investing in oncology capabilities, an in-house companion animal manufacturing facility, and expanding its active pharmaceutical ingredient (API) capacity to meet demand.

Background and context

  • Viyash Scientific Limited is an integrated pharmaceutical company with products and services serving human and animal health segments.
  • The company operates 16 manufacturing facilities with regulatory approvals from USFDA, EU GMP, WHO, and TGA.
  • It has a global presence with operations across India, Spain, Brazil, Turkey, and the USA.
  • Viyash is among the top-25 global animal health companies with a diverse portfolio including 110+ APIs, 30+ human health, and 140+ animal health formulations.

Next milestones

  • Earnings call scheduled for November 14, 2026, at 11:00 AM IST to discuss financial results and take investor questions.
  • The company will focus on execution of investments in oncology and companion animal manufacturing capabilities and API capacity expansion.

More News on General / Other

View all

Latest corporate announcements and market updates in General / Other.

View all news
Viyash Scientific Limited Reports 17.8% Revenue Growth | Stockk News